[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 667
Citations 0
Observation
June 2015

Erythrodermic Epidermolysis Bullosa Acquisita

Author Affiliations
  • 1Department of Dermatology, University of Berne, Inselspital, Berne, Switzerland
  • 2Department of Immunology, University of Berne, Inselspital, Berne, Switzerland
JAMA Dermatol. 2015;151(6):678-680. doi:10.1001/jamadermatol.2015.31

Epidermolysis bullosa acquisita (EBA) is a rare acquired subepidermal blistering autoimmune disease of the skin and mucosae associated with autoantibodies directed against type VII collagen, the major component of the anchoring fibrils of the dermal-epidermal junction.1,2 Various clinical presentations of EBA have been described, including a noninflammatory mechanobullous form, an inflammatory bullous pemphigoid (BP)-like form, and a mucous-membrane pemphigoid-like form. These forms may show clinical overlap, and their courses are often unpredictable.13

Report of a Case

A 60-year-old man was admitted for evaluation of a 3-week history of widespread pruritic cutaneous lesions. The patient had taken no drugs, and his medical history was unremarkable. On examination, almost his entire trunk, buttocks, and thighs were erythematous and infiltrated with papular and urticarial lesions (Figure 1). Islands of normal-appearing skin were observed. On his soles and palms, isolated lesions with a targetlike appearance were noted. The head as well as the oral and genital mucous membranes were spared. During hospital admission, the patient developed isolated vesicles and serous blisters on erythematous skin on his wrist and ankle.

Figure 1.
Clinical Appearance of Erythrodermic Epidermolysis Bullosa Acquisita
Clinical Appearance of Erythrodermic Epidermolysis Bullosa Acquisita

The patient has generalized erythematous confluent papular and urticarial lesions on the trunk.

Light microscopy studies of a skin biopsy specimen obtained from patient’s back showed a diffuse spongiosis with a mixed perivascular inflammatory infiltrate consisting of eosinophils and neutrophils in the upper dermis (Figure 2). Direct immunofluorescence microscopy studies disclosed linear deposits of IgG and C3 along the epidermal basement membrane zone. By indirect immunofluorescence microscopy using sodium chloride–separated normal human skin, circulating IgG autoantibodies binding the dermal side of the split were detected.

Figure 2.
Light Microscopy Study of a Skin Biopsy Specimen From Patient’s Back
Light Microscopy Study of a Skin Biopsy Specimen From Patient’s Back

Specimen shows epidermal spongiosis with a mixed perivascular inflammatory infiltrate composed of eosinophils and neutrophils in the upper dermis (hematoxylin-eosin, original magnification ×40).

Immunoblotting analysis using human dermal extracts showed a reactivity with a 290-kDa protein showing the same electrophoretic migration to the protein band recognized by the control monoclonal antibody directed against type VII collagen.

Based on the clinical features and immunopathological findings, the diagnosis of EBA was made.1 The patient was given oral prednisolone, 0.75 mg/kg of body weight, which resulted in rapid clearance of the lesions within 2 weeks. Corticosteroid doses were subsequently slowly tapered. At a dose of 10 mg/d, the patient experienced a relapse and began treatment with methotrexate, 15 mg subcutaneously once weekly. The prednisolone dose was then tapered to 2.5 mg/d, and the patient remained asymptomatic at 6-month follow-up.

Discussion

The clinical features of EBA are protean. The classic presentation is that of a noninflammatory mechanobullous disease characterized by the development of acral blisters that heal with atrophic scarring, milia, and hyperpigmentation or hypopigmentation. They are localized to trauma-prone surfaces such as elbows, knees, hands, and feet.13 Acral involvement may be mutilating. Scalp involvement occurs in up to 20% of patients.13 The inflammatory BP-like presentation is associated with widespread vesicles and bullae involving intertriginous and flexural areas that heal without atrophic scarring.13 Epidermolysis bullosa acquisita may also present as mucous membrane pemphigoid or as Brunsting-Perry pemphigoid phenotype.3 The potential causes of erythroderma include psoriasis, atopic dermatitis, drug reactions, and cutaneous T-cell lymphoma. With the exception of pemphigus foliaceus, the other autoimmune bullous diseases of the skin have been only anecdotally implicated as cause of erythroderma. Specifically, single cases of erythrodermic BP have been described.4,5 Epidermolysis bullosa acquisita is potentially associated with a number of systemic diseases, including inflammatory bowel diseases,1,3 but our patient showed no evidence of any of these.

Our case was striking because the patient initially showed features suggestive of either a severe drug reaction or a paraviral eruption, but immunopathological studies were diagnostic for EBA. Our observation provides a further example about the polymorphous and misleading presentations of EBA. Hence, EBA should be considered as a rare cause of erythroderma.

Back to top
Article Information

Corresponding Author: Stefanie Häfliger, MD, Universitätsklinik für Dermatologie, Inselspital, 3010 Bern, Schweiz (stefanie.haefliger@insel.ch).

Published Online: March 18, 2015. doi:10.1001/jamadermatol.2015.31.

Conflict of Interest Disclosures: None reported.

Additional Contributions: The authors are indebted to Lionel Fontao, PhD, Department of Dermatology, University of Geneva, for performing the search of anti–type VII collagen antibodies by immunoblotting studies.

References
1.
Gammon  WR, Briggaman  RA.  Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus: diseases of autoimmunity to type VII collagen. Dermatol Clin. 1993;11(3):535-547.
PubMed
2.
Woodley  DT, Chang  C, Saadat  P, Ram  R, Liu  Z, Chen  M.  Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol. 2005;124(5):958-964.
PubMedArticle
3.
Borradori  L, Bernard  P. Pemphigoid group. In: Bolognia  JL, Jorizzo  JL, Schaffer  JV, eds. Dermatology. 3rd ed. New York, NY: Elsevier; 2012:431-445.
4.
Korman  NJ, Woods  SG.  Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol. 1995;133(6):967-971.
PubMedArticle
5.
Amato  L, Gallerani  I, Mei  S, Pestelli  E, Caproni  M, Fabbri  P.  Erythrodermic bullous pemphigoid. Int J Dermatol. 2001;40(5):343-346.
PubMedArticle
×